La cadena de opciones muestra datos clave de las opciones de acciones de Windtree Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Windtree Therapeutics..

Windtree Therapeutics (NASDAQ:WINT) Bolsa, Cadena de Opciones

Windtree Therapeutics

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics Inc

Windtree Therapeutics Inc arrants (25/03/2026)

WINTO GROUP HLDGS LTD by WINTO GROUP HLDGS LTD.

Wintrust Financial Corporation - Common Stock

Wintrust Financial Corp

Wintrust Financial Corporation - Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock, Series D

Wintrust Financial Corporation - Depositary Shares, Each Representing a 1/1,000th Interest in a Share of 6.875% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series E

Barrington Research analyst Vincent Colicchio maintains Barrett Business Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBSI#NASDAQ">BBSI</a>) with a Outperform and maintains $45 price target.

News

Price Target

Analyst Ratings

BBSI

Barrington Research Maintains Outperform on Barrett Business Services, Maintains $45 Price Target

Guidance

OPRX

OptimizeRx Sees FY25 Adjusted EBITDA Of At Least $12M

Sagimet Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.60) by 16.67 percent. This is a 47.06 percent decrease over losses of $(0.34) per share from the same period last year.

Earnings

Earnings Beats

SGMT

Sagimet Biosciences Q4 2024 GAAP EPS $(0.50) Beats $(0.60) Estimate

OptimizeRx Sees FY25 Revenue Of At Least $100M Vs. $99.646M Est.

Needham analyst Matt Dezort reiterates Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on Telosto Hold

THTX

Theratechnologies Presented Data From A Real-world, Observational, Registry Study Demonstrating The Efficacy And Safety Of Ibalizumab In Reducing HIV RNA To Undetectable Levels In Heavily Treatment-experienced Patients With Multidrug Resistant HIV

Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.07 by 42.86 percent. This is a 16.67 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $202.539 million which beat the analyst consensus estimate of $200.579 million by 0.98 percent. This is a 4.29 percent increase over sales of $194.207 million the same period last year.

Sprinklr Q4 2025 Adj. EPS $0.10 Beats $0.07 Estimate, Sales $202.539M Beat $200.579M Estimate

<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/12030007/IMG_0791.jpeg" alt="" class="wp-image-7674" style="width:900px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/12030007/IMG_0791.jpeg 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/12030007/IMG_0791-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/03/12030007/IMG_0791-768x512.jpeg 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The logistics arm of e-commerce giant JD.com reported its 2024 revenue grew nearly 10%, as external customers contributed 70% of the total
JD Logistics Inc.&nbsp;(2618.HK) reported 9.7% revenue growth and a record profit last year, as it diversified its customer base beyond its parent, e-commerce giant JD.com, and boosted its margins through steady technology upgrades and other efficiencies.
The company reported revenue of 182.8 billion yuan ($25.6 billion) for 2024, with external customers supplying 127.8 billion yuan, or about 70% of its total, according to&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2025/0306/2025030600879.pdf">its results</a>&nbsp;released on last Friday. It recorded a non-IFRS annual profit of 7.92 billion yuan, nearly triple the 2.76 billion yuan a year earlier, on greater efficiencies as it upgraded its technology-driven integrated supply chain (ISC) solutions. Its non-IFRS margin rose from 1.7% in 2023 to 4.3% last year. Both the profit and margin were the company's highest since its listing in 2021.
On a quarterly basis, JD Logistics' fourth quarter revenue rose 10.4% year-on-year to 52.1 billion yuan, while its non-IFRS profit rose 23.4% to 2.2 billion yuan, improving for an eighth consecutive quarter.
"Over the past year, we have further consolidated our differentiated competitive advantages centered on ISC solutions and high-quality logistics services by continuously optimizing warehouse network deployment, advancing technological innovations, and enhancing operational efficiency," said CEO Hu Wei on the company's earnings call.
JD Logistics said it has used its industry-specific ISC management services to help its corporate customers across a range of industries, including home appliances, furniture and apparel, to reduce costs and enhance their efficiency by optimizing inventory management, streamlining resource allocation and reducing operating costs.
Revenue from ISC customers last year reached 87.4 billion yuan. Its external ISC customer base totaled 80,703 up 8% from a year earlier.
In 2024, the company said it fully upgraded its digital supply chain technology ecosystem with its "JD Logistics Super Brain", which integrates technologies including AI, big data, and operations research into diverse logistics processes.
At the end of last year, JD Logistics operated a network of over 100 warehouses for its international business with an aggregate gross floor area of over 1 million square meters. Its overseas warehouse network now covers 19 countries and regions.
In its global business, JD Logistics said last year it was supporting a leading Chinese new energy vehicle (NEV) brand with its China-Europe trunk line services. It also said it was supporting another automotive brand with its full cross-border services, including customs clearance, warehousing and distribution in the Middle East.
The company continued to build up its network infrastructure last year to expand its freight delivery and international express delivery services to grab a bigger share of the global e-commerce market. As part of its global build-out, it recently announced that it opened its third warehouse in Poland on Tuesday this week.
JD Logistics was the second unit of JD.com for a separate listing in 2021, raising HK$24.1 billion ($3.1 billion). It was originally set up as JD.com's in-house logistics department in 2007 and has grown since then to become one of the largest players in China's ISC logistics services industry.&nbsp;

Asia

Equities

JD.COM's Logistics Unit Triples Annual Profit On Supply Chain Upgrades

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.27 by 11.11 percent. This is a 15.38 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $32.32 million which beat the analyst consensus estimate of $30.36 million by 6.45 percent. This is a 13.79 percent increase over sales of $28.40 million the same period last year.

OptimizeRx Q4 Adj $0.30 Beats $0.27 Estimate, Sales $32.32M Beat $30.36M Estimate

D. Boral Capital analyst Jason Kolbert maintains VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) with a Buy and maintains $5 price target.

VNRX

D. Boral Capital Maintains Buy on VolitionRX, Maintains $5 Price Target

Evercore ISI Group analyst Cory Kasimov initiates coverage on Summit Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) with a Outperform rating and announces Price Target of $30.

Initiation

SMMT

Evercore ISI Group Initiates Coverage On Summit Therapeutics with Outperform Rating, Announces Price Target of $30

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Werewolf Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOWL#NASDAQ">HOWL</a>) with a Buy and maintains $15 price target.

HOWL

HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target

BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) division&nbsp;QNX introduced a Functional Safety (FuSa) platform designed<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44269547/qnx-launches-functional-safety-platform-to-consolidate-safety-systems-and-ai-workloads" rel="noreferrer noopener"> for advanced robotic systems</a>.
In collaboration with Intel and NexCOBOT, the platform integrates both robotic and safety controls onto a single NexCOBOT board.
This consolidation is intended to help manufacturers and developers reduce costs, minimize power consumption, enhance thermal efficiency, and lower the risk of hardware failures.
This advanced platform is designed to address the increasing need for integrated, safety-certified solutions in industrial automation and robotics.
Optimized for AI-powered environments, it delivers enhanced computing power and virtualization, supporting AI-driven vision systems, real-time motion control, and other critical robotic functions while adhering to safety certification standards.
Grant Courville, SVP, Products and Strategy at QNX, said, &#8220;Based, on our proven track record in delivering safety-certified solutions, developers know that our platform meets the standards of safety and performance.&#8221;
&#8221;Our continued collaboration with Intel and NexCOBOT means we are able to leverage our expertise to create a unified solution that addresses the complex demands of modern robotics and industrial automation.&#8221;
Yesterday, QNX disclosed an expanded collaboration with&nbsp;Advanced Micro Devices&nbsp;to enhance performance in&nbsp;robotic <a target="_blank" href="https://www.benzinga.com/25/03/44245429/blackberry-qnx-expands-support-for-amd-platforms-enhancing-robotic-and-embedded-applications" rel="noreferrer noopener">systems and embedded devices</a>.
Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Future Security ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITE#NYSE">FITE</a>).
Price Action: BB shares are up 1.14% at $4.42 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/mid-cap/25/03/44261077/dan-loeb-pulls-the-plug-on-bath-body-works-stake-as-sales-decline" target="_blank" rel="noreferrer noopener">Dan Loeb Pulls Plug On Bath &amp; Body Works Stake As Sales Decline</a></li>
</ul>
Image via Shutterstock.

Large Cap

Contracts

FITE

BlackBerry QNX Introduces All-in-One Functional Safety Platform for Smarter, Safer Robotics

HC Wainwright &amp; Co. analyst Andres Maldonado reiterates Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) with a Buy and maintains $18 price target.

MURA

HC Wainwright & Co. Reiterates Buy on Mural Oncology, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBIO#NASDAQ">ZBIO</a>) with a Buy and maintains $30 price target.

ZBIO

HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $30 Price Target

Telsey Advisory Group analyst Dana Telsey maintains Stitch Fix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFIX#NASDAQ">SFIX</a>) with a Market Perform and maintains $6 price target.

SFIX

Telsey Advisory Group Maintains Market Perform on Stitch Fix, Maintains $6 Price Target

ARCO

Arcos Dorados Reaffirms 2025 Guidance With 90-100 Restaurant Openings And Capital Expenditures Of $300M-$350M

Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.21 by 33.33 percent. This is a 7.69 percent increase over earnings of $0.26 per share from the same period last year. The company reported quarterly sales of $1.144 billion which missed the analyst consensus estimate of $1.152 billion by 0.71 percent. This is a 2.72 percent decrease over sales of $1.176 billion the same period last year.

Earnings Misses

Arcos Dorados Holdings Q4 2024 GAAP EPS $0.28 Beats $0.21 Estimate, Sales $1.144B Miss $1.152B Estimate

Needham analyst Gil Blum reiterates Geron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) with a Buy and maintains $5 price target.

GERN

Needham Reiterates Buy on Geron, Maintains $5 Price Target

Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) disclosed a collaboration with Singapore Airlines (SIA) to enhance <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44266464/singapore-airlines-and-salesforce-collaborate-on-ai-powered-customer-servicing-applications-plan-t" rel="noreferrer noopener">the customer case management system</a>.
As per the deal, SIA will implement Agentforce, an AI-powered system that automates specific tasks to streamline customer service operations.
Additionally, both companies will work together at Salesforce&#8217;s AI Research hub in Singapore to develop AI-driven solutions for the aviation industry, bringing added value and benefits to airlines.
Powered by Salesforce&#8217;s Data Cloud, which consolidates relevant data, Agentforce enhances AI-driven support by providing tailored recommendations and solutions.
Additionally, SIA will leverage Einstein&#8217;s generative AI within Service Cloud to summarize past customer interactions and offer guidance on assistance.
This will help representatives anticipate needs, customize responses, and reduce response times, enabling more efficient and proactive customer service.
Marc Benioff, Chair and CEO, Salesforce stated, &#8220;We&#8217;re thrilled to partner with Singapore Airlines, a trailblazer in this AI revolution, to elevate their already outstanding customer service to unprecedented heights, augment their employees and collaborate on groundbreaking AI solutions for the airline industry.&#8221;
Goh Choon Phong, Chief Executive Officer, Singapore Airlines, said, &#8220;Integrating Agentforce, Einstein in Service Cloud, and Data Cloud into SIA&#8217;s customer case management system enhances our ability to efficiently assist our customers, and marks the first step in our collaboration. Together, we will co-create AI solutions that drive meaningful and impactful change and set new standards for service excellence in the airline industry.&#8221;
Last week, Salesforce&nbsp;introduced Agentforce 2dx, which is the latest version of its digital labor platform designed to integrate autonomous&nbsp;<a target="_blank" href="https://www.benzinga.com/25/03/44146057/salesforce-unveils-agentforce-2dx-ai-agents-that-work-beyond-chatbots" rel="noreferrer noopener">AI agents into business operations</a>.
Investors can gain exposure to the stock via&nbsp;iShares Expanded Tech-Software Sector ETF&nbsp;(BATS:<a class="ticker" href="https://www.benzinga.com/stock/IGV#BATS">IGV</a>) and&nbsp;REX FANG &amp; Innovation Equity Premium Income ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEPI#NASDAQ">FEPI</a>).
Price Action: CRM shares are up 0.96% at $279.70 premarket at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44200350/salesforce-ai-expansion-sparks-analyst-optimism-400-price-forecast-set" target="_blank" rel="noreferrer noopener">Salesforce Is Trading Below 200-DMA, But Goldman Sachs Sees Huge Stock Upside After Agentforce 2dx Unveil</a></li>
</ul>
Photo: Photo Gonzo via Shutterstock.

FEPI

AI Takes Flight: Singapore Airlines Taps Salesforce For Next-Gen Customer Service Tech

Health Care

Press Releases

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Legal

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

Management

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline

Windtree Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference

Windtree Therapeutics, Inc. Announces Reverse Stock Split

Windtree Files Istaroxime Cardiogenic Shock and Prevention of Arrythmias Patent for India

Windtree Announces Istaroxime Notice of Allowance from the U.S. Patent and Trademark Office for Acute Heart Failure

WINT

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

Entero Therapeutics

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

Vincerx Pharma

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Windtree Therapeutics

Windtree Therapeutics (WINT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL